Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0V5DX
|
|||
| Former ID |
DIB007524
|
|||
| Drug Name |
GR-79236
|
|||
| Synonyms |
GR79236; 124555-18-6; GR-79236; GR 79236; UNII-Q4H682B2VZ; GR 79236X; N-((1S,trans)-2-Hydroxycyclopentyl)adenosine; Q4H682B2VZ; CHEMBL2163568; N-((1S,2S)-2-Hydroxycyclopentyl)adenosine; N-[(1S, trans)-2-Hydroxycyclopentyl]adenosine; N-[(1S,2S)-2-Hydroxycyclopentyl]adenosine; N-[(1S,trans)-2-hydroxycyclopentyl]adenosine; Adenosine, N-(2-hydroxycyclopentyl)-, (1S-trans)-; gr79236x; SCHEMBL2779184; GTPL3288; CHEBI:92714; DTXSID10154427; MolPort-023-276-288; GYWXTRVEUURNEW-TVDBPQCTSA-N; HMS3268O08; ZINC3794575; MFCD00884605
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Diabetic complication [ICD-11: 5A2Y; ICD-9: 253.5, 588.1] | Discontinued in Phase 1 | [1], [2] | |
| Company |
Glaxo Group Research Ltd
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C15H21N5O5
|
|||
| Canonical SMILES |
C1CC(C(C1)O)NC2=C3C(=NC=N2)N(C=N3)C4C(C(C(O4)CO)O)O
|
|||
| InChI |
1S/C15H21N5O5/c21-4-9-11(23)12(24)15(25-9)20-6-18-10-13(16-5-17-14(10)20)19-7-2-1-3-8(7)22/h5-9,11-12,15,21-24H,1-4H2,(H,16,17,19)/t7-,8-,9+,11+,12+,15+/m0/s1
|
|||
| InChIKey |
GYWXTRVEUURNEW-TVDBPQCTSA-N
|
|||
| CAS Number |
CAS 124555-18-6
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| ChEBI ID |
CHEBI:92714
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Adenosine A1 receptor (ADORA1) | Target Info | Agonist | [3] |
| KEGG Pathway | cGMP-PKG signaling pathway | |||
| cAMP signaling pathway | ||||
| Sphingolipid signaling pathway | ||||
| Neuroactive ligand-receptor interaction | ||||
| Morphine addiction | ||||
| NetPath Pathway | TCR Signaling Pathway | |||
| RANKL Signaling Pathway | ||||
| Panther Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||
| Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | ||||
| Reactome | Adenosine P1 receptors | |||
| G alpha (i) signalling events | ||||
| WikiPathways | Nucleotide GPCRs | |||
| GPCRs, Class A Rhodopsin-like | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3288). | |||
| REF 2 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001436) | |||
| REF 3 | Effect of the adenosine A1 receptor agonist GR79236 on trigeminal nociception with blink reflex recordings in healthy human subjects. Cephalalgia. 2003 May;23(4):287-92. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.